Access curated studies on immunology, cellular interactions, vaccine development, and immune-related disorders.
Explore the groundbreaking Phase I/II trial of MB311 (IGN311), a humanized monoclonal antibody targeting Lewis Y antigen for malignant effusions in advanced cancer patients.